Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Morbid Obesity, Noninvasive Ventilation, Deep Sedation
Interventions: High flow nasal cannula, Nasal Cannula; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Drug-induced Tardive Dyskinesia
Interventions: SNC-102, Placebo; Drug
Lead sponsor: Synchroneuron Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Knee Osteoarthritis
Interventions: SM04690, Placebo, Sham; Drug · Other
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 74
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 68 more

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Interventions: IONIS-AGT-LRx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Little Rock, Arkansas • Crystal River, Florida • Hialeah, Florida + 6 more

Conditions: Reduction of Small Intestinal Ulceration Risk
Interventions: Bif195, Placebo; Dietary Supplement · Other
Lead sponsor: Chr Hansen; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Interventions: HLX17, US-sourced Keytruda®; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more

Conditions: Epithelial Ovarian Cancer
Interventions: CA125 assay on Abbott Architect i1000SR platform, HE4 assay on Architect i1000SR platform, Transvaginal Ultrasound; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 25 Years to 80 Years · Female only
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 5
States / cities: Duarte, California • Los Angeles, California • Stanford, California + 2 more

Conditions: Abdominal Pain, Gastritis, Gastric Ulcer, Gastric Cancer
Interventions: MAGNET; Device
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Leukemia, Myeloid, Acute
Interventions: NLA101, Standard of Care (SOC) chemotherapy; Biological · Drug
Lead sponsor: Nohla Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 19 more

Conditions: Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders, Depression Disorder, Depression
Interventions: CYB003, Psychological Support; Drug · Behavioral
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 43
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 36 more

Conditions: Psoriasis
Interventions: Desoximetasone Spray 0.25%, placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hazleton, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Low-fat diet; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: Rivaroxaban, Placebo, Standard of Care (SOC); Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more

Conditions: Renal Transplant Recipient
Interventions: Belatacept, Abatacept; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Open Abdominal Surgery
Interventions: Oblique Subcostal Transversus Abdominis Plane Block, External Oblique Intercostal Fascial Plane block; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stiff Knee Gait, Brain Injuries
Interventions: placebo, botulinum toxin A (BTX-A); Drug
Lead sponsor: Mary Free Bed Rehabilitation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: HIV Infections
Interventions: Atevirdine mesylate, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 9 more

Conditions: Pancreatic Cancer
Interventions: MM-141, Placebo, Gemcitabine, Nab-Paclitaxel; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 47
States / cities: Gilbert, Arizona • Anaheim, California • Fullerton, California + 40 more

Conditions: Asthma
Interventions: Vilanterol, Salmeterol Inhalation Powder, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder Diskus; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Huntington Beach, California • Orlando, Florida • Tallahassee, Florida + 8 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Phoenix, Arizona • Escondido, California • Irvine, California + 10 more

Conditions: ADHD
Interventions: PRC-063 oral capsules, Placebo oral capsules; Drug
Lead sponsor: Purdue Pharma, Canada; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 6
States / cities: Newport Beach, California • Bradenton, Florida • Maitland, Florida + 3 more

Conditions: Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions: RLS-0071, Placebo; Drug
Lead sponsor: ReAlta Life Sciences, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: St. Petersburg, Florida • Glen Burnie, Maryland • Omaha, Nebraska + 1 more

Conditions: Hypertension, Hypertension,Essential
Interventions: Dehydrated Alcohol Injection, USP, Sham procedure; Drug · Procedure
Lead sponsor: Ablative Solutions, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Knoxville, Tennessee

Search by objective public record fields.

Use of High Flow Nasal Cannula During Sedation of Morbidly Obese Patients in the Endoscopy Suite

A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

The Effect of a Probiotic Strain on Ibuprofen-induced GI Damage

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

NLA101 in Adults Receiving High Dose Chemotherapy for AML

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

Low Fat Diet for Fatigue in MS

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

Abatacept Conversion in Kidney Transplantation

EOIFP Block Versus OSTAP Block for Upper Abdominal Surgery

Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)